Administration of a small molecule inhibitor of AP-1 or the senolytic agent ABT-263 reduced expression of genes consistent with an inflammatory tubular cell phenotype and ameliorated inflammation and fibrosis in murine models of transition from acute kidney injury (AKI) to CKD. Here, FOS is linked to chronic kidney disease.